Peter Francis, MD PhD

Chief Scientific Officer, Chief Medical Officer @ Ray Therapeutics, Inc.

About

More than 15 years of translational research experience Expertise in pre-clinical and clinical drug development in the ocular space with particular expertise in gene and stem cell therapies More than 20 clinical trials designed and executed (phase 1, 2, 3) Regulatory accomplishments: Numerous PreIND, RAC, Orphan drug designation, IND submissions Numerous Scientific advisory boards ============= Practicing clinician scientist with more than 20 years experience in ophthalmology. Subspecialy: Retina. Particular expertise in genetic eye disease, translational research, clinical trial design, analysis and implementation. Principal investigator for gene therapy, stem cell therapy and genetic clinical trials. Leadership skills in developing and administering laboratory science, clinical trials center and Reading Center. Specialties: Ophthalmology Retina Genetics Clinical Trials Translational Research

Country

United States

City

Emeryville

Industry

Biotechnology

Skill

Ophthalmology, Clinical Trials, Genetics, Translational Research, Retina, Clinical, Science, Surgery, Pediatrics, Clinical Research, Molecular Biology, Cell, Treatment, Research, Healthcare, Transplantation, Clinical Development, Medical Devices, Diagnostics, Biotechnology

Experience

Chief Scientific Officer, Chief Medical Officer

Ray Therapeutics, Inc.

2022-7 - Present · 4 yrs 3 mos

San Francisco Bay Area

President and Founder

Pacific Ophthalmology Consulting

2012-1 - Present · 14 yrs 9 mos

Portland, Oregon Area

Providing consulting to the pharmaceutical industry, biotechnology companies, venture capital and investors with respect to novel drugs and therapeutics

Chief Scientific Officer and Therapeutic Area Head, Ophthalmology

4D Molecular Therapeutics

2020-2 - 2022-8 · 2 yrs 7 mos

Emeryville, California, United States

Chief Medical Officer and Head of Translational R&D

4D Molecular Therapeutics

2019-1 - 2020-2 · 1 yr 2 mos

Emeryville, CA

SVP Clinical & Translational R&D, & Head of the Ophthalmology Therapeutic Area

4D Molecular Therapeutics

2016-10 - 2019-1 · 2 yrs 4 mos

Emeryville, CA

VP Clinical & Translational R&D, & Head of the Ophthalmology Therapeutic Area

4D Molecular Therapeutics

2015-5 - 2016-10 · 1 yr 6 mos

Physician

Orion Eye Center

2015-5 - 2022-8 · 7 yrs 4 mos

Redmond and Bend, Oregon

Subspecialty practice: Retina

Physician

Orion Eye Center

2012-12 - 2016-7 · 3 yrs 8 mos

20015 SW Pacific Highway, Sherwood, Oregon 97140

Comprehensive ophthalmology with specialities: retina, glaucoma, cataract and laser surgery

Chief Medical Officer

RetroSense Therapeutics

2012-2 - 2016-8 · 4 yrs 7 mos

Member of management team that developed and translated successfully into clinical trials, the first optogenetic therapy for vision restoration, RST-001. Successful biotechnology exit in September 2016: the assets of the company were pruchased by Allergan Inc.

Director

Oregon Health & Science University

2009-1 - 2012-1 · 3 yrs 1 mo

I directed a group that is developing new therapies for eye disease, performing human clinical trials, refining and testing new modalities that measure efficacy of particular treatments

Associate Professor

Oregon Health & Science University

2006-1 - 2011-12 · 6 yrs

Ophthalmologist, Retina Specialist with interest in Age-related macular degeneration and genetic eye diseases

Editor

Ophthalmology International, Greycoat Publishing

2005 - 2011-5 · 6 yrs

Editor for peer reivewed medical journal with international circulation

Senior Lecturer and Consultant Ophthamic Surgeon

St Thomas' Hospital, London

2004 - 2006 · 2 yrs

I provided clinical services in ophthalmology with specific interest in retinal and genetic diseases.

Education

UCL

Ophthalmology, Genetics

1998 - 2000 · 2 yrs

University of Southampton

Medicine

University of Southampton

Cell/Cellular and Molecular Biology